Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multinational, Clinical Trial to Evaluate the Efficacy and Safety of Ranolazine vs Placebo in Patients With Non-ST Segment Elevation Acute Coronary Syndromes

Next Previous
X
Search
Trial Profile

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multinational, Clinical Trial to Evaluate the Efficacy and Safety of Ranolazine vs Placebo in Patients With Non-ST Segment Elevation Acute Coronary Syndromes

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 22 Jul 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ranolazine (Primary) ; Ranolazine (Primary)
  • Indications Acute coronary syndromes; Arrhythmias
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms MERLIN-TIMI-36

    • Most Recent Events

    • 31 Aug 2009 Results presented at the Annual Congress of the European Society of Cardiology (ESC).
    • 07 Nov 2007 Results presented at AHA 2007.
    • 09 Oct 2007 Results reported in Circulation

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top